Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05323955
Title Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (BRIDGET)
Acronym BRIDGET
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Carey Anders, M.D.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.